The cost-effectiveness of using results-based financing to reduce maternal and perinatal mortality in Malawi

• Verfasst von: Chinkhumba, Jobiba [VerfasserIn]
• Verfasst von: De Allegri, Manuela [VerfasserIn]
• Verfasst von: Brenner, Stephan [VerfasserIn]
• Titel: The cost-effectiveness of using results-based financing to reduce maternal and perinatal mortality in Malawi
• Verf.angabe: Jobiba Chinkhumba, Manuela De Allegri, Stephan Brenner, Adamson Muula, Bjarne Robberstad
• E-Jahr: 2020
• Jahr: May 21, 2020
• Umfang: 3 S.
• Fussnoten: Gesehen am 04.11.2020
• Titel Quelle: Enthalten in: BMJ global health
• Ort Quelle: London : BMJ Publishing Group, 2016
• Jahr Quelle: 2020
• Band/Heft Quelle: 5(2020,8) Artikel-Nummer e002260, 13 Seiten
• ISSN Quelle: 2059-7908
• DOI: doi:10.1136/bmjgh-2019-002260
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: child health
• Sach-SW: health economics
• Sach-SW: maternal health
• Sach-SW: public health
• K10plus-PPN: 1737625520

Abstract

Introduction Results-based financing (RBF) is being promoted to increase coverage and quality of maternal and perinatal healthcare in sub-Saharan Africa (SSA) countries. Evidence on the cost-effectiveness of RBF is limited. We assessed the cost-effectiveness within the context of an RBF intervention, including performance-based financing and conditional cash transfers, in rural Malawi. - Methods We used a decision tree model to estimate expected costs and effects of RBF compared with status quo care during single pregnancy episodes. RBF effects on maternal case fatality rates were modelled based on data from a maternal and perinatal programme evaluation in Zambia and Uganda. We obtained complementary epidemiological information from the published literature. Service utilisation rates for normal and complicated deliveries and associated costs of care were based on the RBF intervention in Malawi. Costs were estimated from a societal perspective. We estimated incremental cost-effectiveness ratios per disability adjusted life year (DALY) averted, death averted and life-year gained (LYG) and conducted sensitivity analyses to how robust results were to variations in key model parameters. - Results Relative to status quo, RBF implied incremental costs of US$1122, US$26 220 and US$987 per additional DALY averted, death averted and LYG, respectively. The share of non-RBF facilities that provide quality care, life expectancy of mothers at time of delivery and the share of births in non-RBF facilities strongly influenced cost-effectiveness values. At a willingness to pay of US$1485 (3 times Malawi gross domestic product per capita) per DALY averted, RBF has a 77% probability of being cost-effective. - Conclusions At high thresholds of wiliness-to-pay, RBF is a cost-effective intervention to improve quality of maternal and perinatal healthcare and outcomes, compared with the non-RBF based approach. More RBF cost-effectiveness analyses are needed in the SSA region to complement the few published studies and narrow the uncertainties surrounding cost-effectiveness estimates.